Riskpilot← Back to searchSign inGet full accessSinamsar Medical AB
ABActiveOrg 5567664940Sveavägen 45Other human health activities n.e.c. · NACE 8699Est. 20080 employees
Revenue 2025
SEK 659K
-18% vs 2024
EBITDA margin
55.0%
-27% vs 2024
Equity ratio
79.1%
Financial strength
Net profit 2025
SEK 486K
-5% vs 2024
| Revenue | SEK 659K | -18% |
| EBITDA | SEK 363K | -27% |
| Net profit | SEK 486K | -5% |
| Total assets | SEK 2,8M | -8% |
| Equity | SEK 2,2M | -1% |
| Employees | 0 | — |
Legal name
Sinamsar Medical AB
Org number
5567664940
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
30 september 2008
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets verksamhet är att bedriva läkarpraktik och konsult- verksamhet inom medicinområdet, handel med värdepapper och fastigheter samt därmed förenlig verksamhet.
Address
Sveavägen 45
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 062 | 1 032 | 811 | 804 | 659 |
| Staff expenses | — | −4 | −10 | −17 | −7 |
| EBITDA | 842 | 806 | 561 | 494 | 363 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 842 | 806 | 561 | 494 | 363 |
| Net financials | 179 | −63 | −943 | 70 | 72 |
| Profit before tax | 891 | 853 | −282 | 654 | 620 |
| Tax | −160 | −217 | −155 | −144 | −134 |
| Net profit | 731 | 636 | −437 | 510 | 486 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 074 | 3 477 | 2 830 | 3 048 | 2 815 |
| Equity | 1 832 | 2 318 | 1 881 | 2 241 | 2 227 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 342 | 369 | 259 | 207 | 173 |
| Total debt | 342 | 369 | 259 | 207 | 173 |
EBITDA margin
55.0%
This company
15.8%
Market median
+248% vs market
20212025
Equity ratio
79.1%
This company
38.2%
Market median
+107% vs market
20212025
Return on equity
21.8%
This company
18.4%
Market median
+18% vs market
20212025
Net profit margin
73.6%
This company
8.1%
Market median
+809% vs market
20212025
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20212025
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sinamsar Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gundars Dags Rasmanis | Board of Directors | 0 companies |
| Elsie Birgitta Welin-Berger | Deputy Board Member | 0 companies |